LA SR186

Creates a Task Force on Alternative Therapies for Veterans to study whether psychedelic therapies (including MDMA, psilocybin, ketamine, and ibogaine) may benefit Louisiana veterans suffering from traumatic brain injuries, PTSD, depression, and anxiety

Task force consists of 9 members including the Senate Health and Welfare Committee chairman, governor's designee, secretaries of Louisiana Health and Veterans Affairs departments, LSU Health chancellors, Louisiana Hospital Association president, a physician with veteran treatment experience, and one veteran

Requires review of clinical trials, current literature, FDA actions, treatment guidelines, and patient access considerations for psychedelic therapies treating PTSD, depression, and co-occurring conditions

Written report with recommendations and specific legislative proposals due to the legislature by February 1, 2026, after which the task force terminates

Members serve without compensation; designee names must be submitted by August 1, 2025; majority constitutes quorum for official actions